Voices
Rashid Lui: First-in-Class Oral Selective p53 Reactivator Looks Promising
Rashid Lui/X

Rashid Lui: First-in-Class Oral Selective p53 Reactivator Looks Promising

Rashid Lui, Associate Consultant at Hospital Authority and Honorary Clinical Assistant Professor at CUHK Medicine, shared a post on LinkedIn:

“And this is why, ladies and gentlemen, I have pivoted more and more towards oncology

This latest phase I study in NEJM Group of a first-in-class, Oral selective p53 reactivator looks promising

Cancer biomarkers and pathways that we were forced to study in med school are now potentially druggable!”

Title: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Authors: Ecaterina Dumbrava, Geoffrey Shapiro, Aparna Parikh, Melissa Johnson, Anthony Tolcher, John Thompson, Anthony El-Khoueiry, Andrae Vandross, Shivaani Kummar, Dale Shepard, Kim LeDuke, Lisa Sheehan, Leila Alland, Arshad Haque, Deepika Jalota, Marc Fellous, Alison Schram

Read the Full Article.

Rashid Lui: First-in-Class Oral Selective p53 Reactivator Looks Promising

Other articles featuring Rashid Lui.

Alison Schram Andrae Vandross Anthony El-Khoueiry Anthony Tolcher Aparna Parikh Arshad Haque cancer Dale Shepard Deepika Jalota Ecaterina Dumbrava Geoffrey Shapiro John Thompson Kim LeDuke Leila Alland Lisa Sheehan Marc Fellous Melissa Johnson NEJM Group OncoDaily Oncology Rashid Lui Shivaani Kummar